Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma

Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.


The breaking of peripheral T-cell tolerance toward self-antigens expressed by tumor cells and the subsequent establishment of an effective tumor protective immune response remains a major challenge for cancer immunotherapy. We report that both protective and therapeutic anti-tumor immune responses can be achieved in a mouse leukemia/lymphoma tumor model through the strong adjuvant effects provided by allogeneic CD3/CD28 cross-linked Th1 memory cells. The adjuvant effect of these cells is mediated by their ability to produce a variety of 'danger signals' which serve to deviate native non-protective Th2 anti-leukemia immune responses to effective Th1 immune responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • CD28 Antigens / immunology
  • CD3 Complex / immunology
  • Cancer Vaccines / immunology
  • Cell Differentiation / immunology
  • Cyclin D1 / immunology
  • Female
  • Immunologic Memory
  • Immunotherapy, Active / methods*
  • Leukemia / immunology
  • Leukemia / therapy*
  • Lymphoma / immunology
  • Lymphoma / therapy*
  • Male
  • Mice
  • Th1 Cells / cytology
  • Th1 Cells / immunology
  • Th1 Cells / transplantation*
  • Transplantation, Homologous / immunology*


  • Antigens, Neoplasm
  • CD28 Antigens
  • CD3 Complex
  • Cancer Vaccines
  • Cyclin D1